Sarah Glickman
APTARGROUPAbout Sarah Glickman
Independent director of AptarGroup, Inc. since 2023; age 55; member of the Audit Committee and designated by the Board as an “audit committee financial expert.” Currently Chief Financial Officer and Principal Accounting Officer of Criteo S.A. (since September 2020). Her ATR board term continues until the 2027 annual meeting. Background spans senior finance and transformation roles at XPO, Novartis, Honeywell, and Bristol‑Myers Squibb; began career at PricewaterhouseCoopers .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Criteo S.A. | Chief Financial Officer & Principal Accounting Officer | Since Sep 2020 | Public company CFO; capital markets, reporting, controls |
| XPO, Inc. | Acting CFO; previously SVP, Corporate Finance & Transformation | Not disclosed | Led finance/transformation at large public issuer |
| Novartis; Honeywell; Bristol‑Myers Squibb | Global executive roles | Not disclosed | Finance/operations leadership experience |
| PricewaterhouseCoopers | Early career | Not disclosed | Audit/accounting foundation |
External Roles
| Organization | Role | Public/Private | Tenure | Committee/Chair |
|---|---|---|---|---|
| 2seventy bio, Inc. | Director | Public | Since 2021 | Audit Committee Chair |
| Criteo S.A. | Executive (CFO/PAO) | Public | Since Sep 2020 | N/A (executive, not board) |
Board Governance
- Independence: Board determined Ms. Glickman is independent under NYSE standards; ATR has 9 of 10 independent directors .
- Committees: Audit Committee member; Audit held 8 meetings in 2024; Board held 7; no director fell below 75% attendance .
- Financial expert: Board designated her an “audit committee financial expert” .
- Engagement: Attended the 2024 annual meeting of stockholders .
- Chair/Leadership context: Independent Chair (Candace Matthews). Independent directors meet in executive session with each regular Board meeting .
Fixed Compensation (Director)
| Component | Structure | 2024 Amount (USD) |
|---|---|---|
| Annual Board retainer (cash) | Non‑employee director retainer | $100,000 |
| Audit Committee member retainer (cash) | Member | $11,000 |
| Total cash fees earned (2024) | Retainers above | $111,000 |
| Other cash fees | Meeting fees | Not disclosed |
| Matching gifts | Company matches eligible donations up to $6,000 | Program availability (no amount reported for Ms. Glickman) |
Performance Compensation (Director Equity)
| Grant Type | Grant Date | Shares/Units | Grant-Date Fair Value | Vesting Notes |
|---|---|---|---|---|
| Annual RSU grant | May 1, 2024 | 1,113 RSUs | $160,072 (valued at $143.82/share) | Standard board RSU grant; vesting schedule not specified in proxy |
| Options/PSUs (Director) | — | — | — | Non‑employee director equity described as RSUs; options/PSUs for directors not disclosed |
Equity plan guardrails: Non‑employee director compensation capped at $500,000 per fiscal year under the 2018 Plan; prohibition on repricing; minimum 1‑year vesting on 95% of shares; director awards subject to clawback policy .
Other Directorships & Interlocks
| Company | Role | Potential Conflict With ATR? |
|---|---|---|
| 2seventy bio, Inc. | Director; Audit Chair | None disclosed; ATR Audit Committee oversees related‑party policy |
- Related‑party transactions: None requiring disclosure since January 1, 2024; Audit Committee (of which she is a member) approves related‑person transactions per policy .
- Time commitments: Corporate Governance Committee annually reviews directors’ outside roles and time commitments .
Expertise & Qualifications
- Finance/accounting leadership in public companies; risk management; strategic planning; designated audit committee financial expert .
- Audit Committee oversight scope at ATR includes financial reporting, internal controls, auditor oversight, related‑party approvals, ESG disclosure controls, and cybersecurity oversight/disclosure processes .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | RSUs/Options Vesting Within 60 Days (as of Mar 14, 2025) |
|---|---|---|---|
| Sarah Glickman | 2,007 | <1% | 1,113 |
| Notes | Beneficial ownership includes sole voting/dispositive power unless noted | Based on 65,966,138 shares outstanding plus individual’s 60‑day exercisable/vesting awards | RSUs/Options column reflects awards vesting within 60 days of record date |
| Citations: . |
- Ownership alignment: Non‑executive directors must hold ≥5× annual cash retainer ($500,000) within 5 years; as of record date, each non‑employee director is either compliant or within phase‑in .
- Hedging/pledging: Prohibited for directors under Insider Trading Policy .
- Section 16 compliance: Company states all 2024 Section 16 filings were timely except one Form 4 for another executive; no exception noted for directors as a group .
Governance Assessment
-
Strengths
- Independent director with deep public‑company CFO experience; Board‑designated audit committee financial expert, reinforcing audit quality and risk oversight .
- Active Audit Committee agenda (8 meetings in 2024) covering financial reporting, auditor independence, related‑party reviews, ESG disclosure controls, and cybersecurity oversight including incident disclosure processes—material for investor confidence in controls .
- Strong attendance/engagement (no director below 75%; attended 2024 annual meeting) .
- Director pay structure balanced (cash + RSUs), within plan caps; equity grants subject to clawback; no hedging/pledging permitted—alignment with shareholders .
- Board practices: independent Chair; regular executive sessions; majority voting and resignation policy; robust independence standards—supportive of board effectiveness .
-
Risks/Red Flags
- None identified in filings regarding related‑party transactions, pledging/hedging, or attendance for Ms. Glickman; Company reports no related‑party transactions requiring disclosure since Jan 1, 2024 .
- Workload consideration: Concurrent CFO role at Criteo and external public board service; ATR’s Governance Committee annually evaluates directors’ outside time commitments, which mitigates risk .
-
Investor sentiment context
- Say‑on‑pay support of ~97.4% at 2024 meeting (five‑year average ~97%) signals broad shareholder confidence in ATR’s compensation/governance approach (contextual to board oversight) .
Appendix: Board Compensation Program Reference (context)
- Annual non‑employee director cash retainer: $100,000; Audit Committee member retainer: $11,000; Audit Chair: $28,000 (for reference, not applicable to Ms. Glickman); annual RSU grant ≈ $160,000 (Chair ≈ $187,500) granted May 1, 2024 (1,113 RSUs; Chair 1,304 RSUs; fair value $143.82/share) .
All citations: .